Current funding opportunities

Expected Outcome:

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• The scientific and clinical communities make effective use of state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to underpin and complement the development of innovative interventions aimed at more effective treatments for neurodegenerative diseases.
• The scientific and clinical communities benefit from the exchange of data, knowledge and best practices, thereby strengthening their collaboration in the EU, the Associated Countries and beyond.
• The scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR^[1] principles, thereby encouraging further use of the data.
• Policymakers, funders, scientific and clinical communities, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
• Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to some of the following expected outcomes:

• Researchers, healthcare practitioners and providers in low- and middle-income countries (LMICs)^[1] and/or those in high-income countries (HICs) serving disadvantaged populations have access to improved insights and evidence on how to equitably promote the early prevention, risk reduction, and timely diagnosis of Non-Communicable Diseases (NCDs) in children and/or young people.
• Policymakers, public health managers and authorities, parents and their children, and young adults have access to evidence and recommendations for national programmes and policies to improve quality of life in children and/or young people and extend healthy life expectancy.
• Researchers, clinicians, policymakers, public health managers and authorities have an improved understanding how to effectively adapt and/or scale up interventions for prevention and management of chronic NCDs in children and/or young people at local, regional, and national levels.
• Communities, parents and their children, young adults, local stakeholders and authorities are fully engaged in implementing and taking up interventions that tackle NCDs in children and/or young people.

Expected Outcome:

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:

• Researchers, developers and clinical practitioners have access to state-of-the-art knowledge, data, technologies, tools, methods, best practices, and trainings to develop innovative healthcare interventions aimed at reducing burden of the following specific Non-Communicable Diseases (NCDs): cardiovascular diseases, diabetes, chronic respiratory diseases or chronic kidney diseases.
• Scientific and clinical communities can use innovative healthcare interventions to generate meaningful advances in clinical practice and care for patients with NCDs following validation in late-stage clinical trials.
• Scientific and clinical communities make wide use of relevant databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR^[1] principles, thereby encouraging further use of the data.
• Policymakers, scientific and clinical communities, developers, patient organisations, regulators, and other relevant bodies are informed of the research advances made and the requirements for a widespread implementation of the innovative therapeutic interventions and complementary approaches.
• Patients and caregivers are constructively engaged with the research, ensuring that their needs are catered for, with the aim of tangibly benefitting from the interventions.

Expected Outcome:

Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:

• Researchers and health professionals gain a deeper understanding of the functional effects of tumour heterogeneity during cancer initiation and progression, supporting the identification of more precise and novel therapeutic targets.
• Researchers, health professionals and innovators benefit from improved knowledge and tools to support the discovery and development of next generation genomically-informed cancer treatments.
• Researchers, innovators, and professionals across disciplines and sectors contribute to the UNCAN.eu research data platform by ensuring data interoperability, and enabling sustainable access to newly developed digital tools and models for the analysis and management of multimodal clinical data.

Expected Outcome:

• Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:
  • Patients afflicted by lung, bowel, breast or prostate cancer^[1], will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures^[2].
  • Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators^[3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.
  • National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

Expected Outcome:

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities;
• Researchers, physicians, innovators^[1], startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation;
• National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems;

Expected Outcome:

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• People at risk of cancer, cancer patients and their caregivers/families benefit from access to more effective and cost-effective, national or regional, cancer control programmes across EU Member States and Associated Countries.
• Researchers, physicians, innovators^[1], SMEs and other professionals from different disciplines and sectors have access to national, regional or local data on healthcare spending (such as expenditures, resource allocations, organisation and type of healthcare interventions, and for which cancer indications, infrastructure, medical prescriptions, drug pricing, drug sales, reimbursement data from health insurers, population-based cancer registries or other cancer-centred registry data, longitudinal epidemiology data) for research and commercial purposes.
• National or regional healthcare systems, healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to improve equitable health outcomes of cancer patients by addressing direct and indirect costs, delivering value-driven cancer care and tackling organisational challenges of a rapidly-changing, dynamic cancer control^[2] landscape.

Expected Outcome:

This action supports the follow-up to the July 2023 Communication on EU Missions assessment^[1]. Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:

• Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions.
• The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models.
• Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer.
• Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment.
• Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research.